Walpar Nutritions Limited is a specialized Indian healthcare and wellness enterprise engaged in the manufacturing and trading of pharmaceutical, nutraceutical, herbal, and ayurvedic products. Originally established as a partnership firm in **2009**, the company transitioned to a public limited entity in **December 2020**. Today, it operates as an integrated player leveraging advanced manufacturing technologies and a robust R&D framework to serve domestic and international markets. --- ### **Core Business Segments and Product Portfolio** The company operates through a **single primary business segment**: the **Manufacturing and Trading of Pharmaceutical, Nutraceutical, Herbal, and Ayurvedic commodities**. Its operations are diversified across several high-growth healthcare verticals: * **Nutraceuticals:** Focus on immunity-boosting supplements and preventive healthcare formulations. * **Pharmaceuticals:** Production of branded and generic medicinal products. * **Herbal & Ayurvedic:** Development of plant-based remedies and traditional formulations. * **Dermo-Cosmetics:** Specialized skincare and wellness products managed through strategic partnerships. * **Distribution Channels:** A multi-channel approach utilizing **institutional sales**, **offline distribution networks**, and a growing **online/e-commerce presence**. --- ### **Corporate Structure and Strategic Group Entities** Walpar manages its specialized operations through a parent entity and a network of subsidiaries and associates, allowing for focused growth in niche segments like dermo-cosmetics and wellness. | Entity Name | Relationship | Holding % | Strategic Role | | :--- | :--- | :--- | :--- | | **Walpar Wellness Private Limited (WWPL)** | Subsidiary | **60.00%** | Core wellness and consumer health focus. | | **Walpar Nutri Science Private Limited (WNSPL)** | Subsidiary | **50.67%** | Specialized nutritional science and R&D. | | **Pallota Nutritions Private Limited** | Associate | Incorporated **July 2025** | Newest strategic expansion vehicle. | | **Steer Peau Dermo Cosmetique Pvt Ltd** | Related Party | Strategic Partner | Focus on dermatological and cosmetic formulations. | --- ### **Financial Performance and Operational Metrics** The company has demonstrated consistent growth in scale and profitability over the last two fiscal years, characterized by improved operational leverage. **Comparative Financial Summary (Values in ₹ Crore):** | Metric | FY 2024-25 (Consolidated) | FY 2023-24 (Consolidated) | FY 2024-25 (Standalone) | FY 2023-24 (Standalone) | | :--- | :---: | :---: | :---: | :---: | | **Total Revenue** | **72.03** | **62.74** | **60.26** | **51.44** | | **Profit Before Tax (PBT)** | **3.88** | **2.49** | **2.43** | **1.48** | | **Net Profit (PAT)** | **2.80** | **1.95** | **1.69** | **1.11** | **Key Financial Observations:** * **Revenue Growth:** Consolidated revenue increased by **14.8%** YoY; Standalone revenue grew by **17.1%**. * **Profitability Surge:** Consolidated Net Profit rose by **43.6%**, indicating strong margin expansion. * **Operational Efficiency:** Standalone PBT improved by **64.2%**, reflecting successful cost management and higher productivity. * **Contingent Liabilities:** Reported as **Nil** as of **March 31, 2025**, indicating a clean balance sheet regarding unforeseen claims. --- ### **Capital Structure and Corporate Actions** Walpar is actively restructuring its capital base to support both organic and inorganic growth opportunities. * **Bonus Issue:** In August 2024, the company executed a **1:1 Bonus Issue**, doubling its paid-up equity share capital from **₹4.69 Crore** to **₹9.39 Crore** (**93,90,440 shares** at **₹10** par value). * **Borrowing & Investment Limits:** Shareholders have approved an increase in borrowing limits up to **₹100 Crore** (above paid-up capital and free reserves). Similarly, the limit for loans and investments under Section 186 has been set at **₹100 Crore**. * **Subsidiary Support:** The company provided a corporate guarantee of **₹5.64 Crore** in March 2026 for a term loan availed by **Walpar Wellness Private Limited** through **SIDBI**. * **Related Party Transactions:** To facilitate seamless group operations, the company sought approval for transactions up to **₹100 Crore** each with **WNSPL**, **Pallota Nutritions**, and **Steer Peau Dermo Cosmetique** for **FY 2025-26**. --- ### **Strategic Growth Drivers and Market Expansion** The company’s forward-looking strategy is built on four primary pillars: 1. **Global Market Penetration:** Expanding the export footprint into the **US, Europe, and Asia-Pacific** regions, targeting the rising global demand for plant-based and immunity products. 2. **Regulatory Tailwinds:** Leveraging Indian government incentives including the **PLI scheme**, **Startup India**, and **Ayush Promotion** initiatives. 3. **Technological Innovation:** Utilizing **coal gasification technology** for chemical production efficiency and investing in **evidence-based herbal formulations**. 4. **Operational Excellence:** Aligning manufacturing facilities with international standards (**USFDA, CDSCO, FSSAI**) and enhancing **digital marketing** for B2B and B2C segments. --- ### **Risk Management and Governance Framework** Walpar operates in a high-stakes environment requiring proactive mitigation of industry-specific risks. * **Market & Competitive Risk:** The company faces fierce competition from domestic branded generics and international players, which may pressure profit margins. * **Regulatory & Compliance Risk:** Stringent oversight from **CDSCO, FSSAI, and USFDA** necessitates constant investment in quality control and R&D. * **Supply Chain & Input Costs:** Volatility in the prices of natural extracts and raw materials, alongside geopolitical factors, impacts cost structures. * **Credit Risk:** Management monitors potential defaults on receivables, particularly in diversified operations. As of **March 31, 2024**, no impairment was deemed necessary. * **Governance & Shareholding:** * **Promoter Holding:** Mr. Kalpesh Pravinchandra Ladhawala (MD) holds **17,24,000** shares (**18.36%**). He was recently re-appointed for a three-year term (**2026–2029**). * **Key Managerial Interests:** **Ms. Nidhi Yogeshkumar Shah** holds **6.26%** and **Mr. Fenil Prakashkumar Shah** holds **1.28%** of equity. * **Executive Compensation:** Remuneration for key management was revised to **₹11,70,000** for **2024-25**, reflecting the company's growth in scale.